E
Enrique M. Ocio
Researcher at University of Cantabria
Publications - 264
Citations - 9830
Enrique M. Ocio is an academic researcher from University of Cantabria. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 52, co-authored 224 publications receiving 8113 citations. Previous affiliations of Enrique M. Ocio include Spanish National Research Council & Purdue University.
Papers
More filters
Journal ArticleDOI
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesús F. San-Miguel,V. Hungria,Sung-Soo Yoon,Meral Beksac,Meletios A. Dimopoulos,Ashraf Elghandour,Wiesław Wiktor Jędrzejczak,Andreas Günther,Thanyaphong Na Nakorn,Noppadol Siritanaratkul,Paolo Corradini,Suporn Chuncharunee,Je-Jung Lee,Robert L. Schlossman,Tatiana Shelekhova,Kwee Yong,Daryl Tan,Tontanai Numbenjapon,Jamie Cavenagh,Jian Hou,Richard Leblanc,Hareth Nahi,Lugui Qiu,Hans Salwender,Stefano Pulini,Philippe Moreau,Krzysztof Warzocha,Darrell White,Joan Bladé,Wenming Chen,Javier de la Rubia,Peter Gimsing,Sagar Lonial,Jonathan L. Kaufman,Enrique M. Ocio,Ljupco Veskovski,Sang Kyun Sohn,Ming Chung Wang,Jae Hoon Lee,Hermann Einsele,Monika Sopala,Claudia Corrado,Bourras Rezki Bengoudifa,Florence Binlich,Paul G. Richardson +44 more
TL;DR: Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical studies has synergistic anti-myeloma activity when combined with bortezomib and dexamethasone and the proportion of patients achieving an overall response did not differ between treatment groups.
Journal ArticleDOI
International prognostic scoring system for Waldenstrom macroglobulinemia
Pierre Morel,Alain Duhamel,Paolo G. Gobbi,Meletios A. Dimopoulos,Madhav V. Dhodapkar,Jason McCoy,John Crowley,Enrique M. Ocio,Ramón García-Sanz,Steven P. Treon,Véronique Leblond,Robert A. Kyle,Bart Barlogie,Giampaolo Merlini +13 more
TL;DR: The ISSWM retained its prognostic significance in subgroups defined by age, treatment with alkylating agent, and purine analog, and may provide a means to design risk-adapted studies.
Journal ArticleDOI
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal,Paul G. Richardson,S. Vincent Rajkumar,Jesús F. San-Miguel,Meral Beksac,Ivan Spicka,Xavier Leleu,Fredrik Schjesvold,Fredrik Schjesvold,Philippe Moreau,Meletios A. Dimopoulos,Jeffrey Shang Yi Huang,Jiri Minarik,Michele Cavo,H. Miles Prince,Sandrine Macé,Kathryn P. Corzo,Frank Campana,Solenn Le-Guennec,Franck Dubin,Kenneth C. Anderson,Vincent Rajkumar,Simon J. Harrison,Wojt Janowski,Ian Kerridge,Andrew Spencer,Michel Delforge,Karel Fostier,Philip Vlummens,Ka Lung Wu,Richard Leblanc,Michel Pavic,Michael Sebag,Roman Hájek,Vladimir Maisnar,Ludek Pour,Henrik Gregersen,Lotfi Benbouker,Denis Caillot,Martine Escoffre-Barbe,Thierry Facon,Laurent Frenzel,Cyrille Hulin,Lionel Karlin,Brigitte Kolb,Brigitte Pegourie,Aurore Perrot,Mourad Tiab,Laure Vincent,Dietger Niederwieser,Achilles Anagnostopoulos,Sosana Delimpasi,Marie Christine Kyrtsonis,Anargyros Symeonidis,Árpád Illés,Gabor Mikala,Zsolt Nagy,Sara Bringen,Paolo Corradini,Ciceri Fabio,Roberto M. Lemoli,Anna Marina Liberati,Chiara Nozzoli,Renato Zambello,Shinsuke Iida,Takashi Ikeda,Satoshi Iyama,Morio Matsumoto,Chihiro Shimazaki,Kazutaka Sunami,Kenshi Suzuki,Michihiro Uchiyama,Youngil Koh,Ki-Hyun Kim,Jae Hoon Lee,Chang-Ki Min,Hillary Blacklock,Hugh Goodman,AJ Neylon,David Simpson,Sebastian Grosicki,Artur Jurczyszyn,Adam Walter-Croneck,Krzysztof Warzocha,Luis Araujo,Claudia Moreira,Vadim A Doronin,Larisa P. Mendeleeva,Vladimir I. Vorobyev,Andrej Vranovsky,Adrian Alegre,Mercedes Gironella,Marta Sonia Gonzalez Perez,Carmen Montes,Enrique M. Ocio,Paula Rodriguez,Mats Hardling,Birgitta Lauri,Ming Chung Wang,Su Peng Yeh,Mutlu Arat,Fatih Demirkan,Zafer Gulbas,Sevgi Kalayoglu Besisik,Ihsan Karadogan,Tulin Tuglular,Ali Ünal,Filiz Vural,Jonathan Sive,Matthew Streetly,Kwee Yong,Jason Tache +111 more
TL;DR: The aim of this study was to determine the progression-free survival benefit of isatuximab plus pomalidomide and dexamethasone compared with pomidine and dexAMethas one in patients with relapsed and refractory multiple myeloma.
Journal ArticleDOI
The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes
Soraya Tabera,José A. Pérez-Simón,María Díez-Campelo,Luis Ignacio Sánchez-Abarca,Belén Blanco,Antonio López,Ana Benito,Enrique M. Ocio,Fermín Sánchez-Guijo,Consuelo del Cañizo,Jesús F. San Miguel +10 more
TL;DR: The findings of this study indicate that mesenchymal stem cells promote survival and inhibit proliferation and maturation of B cells, and support a role of these cells in the immune response.
Journal ArticleDOI
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
Jens Hillengass,Saad Z. Usmani,S. Vincent Rajkumar,Brian G.M. Durie,Maria-Victoria Mateos,Sagar Lonial,Cristina João,Kenneth C. Anderson,Ramón García-Sanz,Eloisa Riva,Juan Du,Niels W.C.J. van de Donk,Jesus G. Berdeja,Evangelos Terpos,Elena Zamagni,Robert A. Kyle,Jesus San Miguel,Hartmut Goldschmidt,Sergio Giralt,Shaji Kumar,Noopur Raje,Heinz Ludwig,Enrique M. Ocio,Rik Schots,Hermann Einsele,Fredrik Schjesvold,Wenming Chen,Niels Abildgaard,Brea Lipe,Dominik Dytfeld,Baldeep Wirk,Matthew T. Drake,Michele Cavo,Juan José Lahuerta,Suzanne Lentzsch +34 more
TL;DR: Recommendations on imaging within and outside of clinical trials will help standardise imaging for monoclonal plasma cell disorders worldwide to allow the comparison of results and the unification of treatment approaches for multiple myeloma.